Currently enrolling: HYPERION Phase 3 clinical trial to evaluate Sotatercept on top of background pulmonary arterial hypertension therapy in newly diagnosed intermediate-and high-risk patients

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background pulmonary arterial hypertension therapy in newly diagnosed intermediate- or high risk pulmonary arterial hypertension participants. The estimated enrolment is participants is 662 and the estimated completion date is August 31, 2028. The sponsor is Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA.

Read more at this link on the ClinicalTrials.gov website

Last Update Posted: May 17, 2023